ArticleMolecular pharmacology2024
Circumvention of Topoisomerase II
Xinyi Wang, Jessika Carvajal-Moreno, Xinyu Zhao, Junan Li, Victor A Hernandez, Jack C Yalowich, Terry S Elton
Abstract read
In one paragraphArticle in Molecular pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Xinyi WangDivision of Pharmaceutics and Pharmacology, College of Pharmacy (X.W., J.C.-M., X.Z., V.A.H., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.L.), The Ohio State University, Columbus, Ohio.
Jessika Carvajal-MorenoDivision of Pharmaceutics and Pharmacology, College of Pharmacy (X.W., J.C.-M., X.Z., V.A.H., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.L.), The Ohio State University, Columbus, Ohio.
Xinyu ZhaoDivision of Pharmaceutics and Pharmacology, College of Pharmacy (X.W., J.C.-M., X.Z., V.A.H., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.L.), The Ohio State University, Columbus, Ohio.
Junan LiDivision of Pharmaceutics and Pharmacology, College of Pharmacy (X.W., J.C.-M., X.Z., V.A.H., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.L.), The Ohio State University, Columbus, Ohio.ORCID 0000-0003-0381-9356 Victor A HernandezDivision of Pharmaceutics and Pharmacology, College of Pharmacy (X.W., J.C.-M., X.Z., V.A.H., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.L.), The Ohio State University, Columbus, Ohio.
Jack C YalowichDivision of Pharmaceutics and Pharmacology, College of Pharmacy (X.W., J.C.-M., X.Z., V.A.H., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.L.), The Ohio State University, Columbus, Ohio yalowich.1@osu.edu elton.8@osu.edu.ORCID 0000-0001-5414-573X Terry S EltonDivision of Pharmaceutics and Pharmacology, College of Pharmacy (X.W., J.C.-M., X.Z., V.A.H., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.L.), The Ohio State University, Columbus, Ohio yalowich.1@osu.edu elton.8@osu.edu.ORCID 0000-0001-8034-8741 Funding
Novel Topoisomerase II alpha isoform as a drug resistance determinantR01CA226906 · NCI · OHIO STATE UNIVERSITY · PI ELTON, TERRY S, YALOWICH, JACK C. · 2019 to 2023
$1.8MNCI NIH HHS R01 CA226906
6 · The paper itselfAbstract
Indexed as
DNA Topoisomerases, Type IIDrug Resistance, NeoplasmEtoposideIntronsPoly APoly-ADP-Ribose Binding ProteinsBase SequenceCRISPR-Cas SystemsExonsK562 CellsRNA, MessengerDNA Topoisomerases, Type IIEtoposidePoly ApolyadeninePoly-ADP-Ribose Binding ProteinsRNA, MessengerTOP2A protein, human
Identifiers
PMID38719474
PMCPMC11187689
What OpenQuestion holds
Textmetadata
Read underepoch 390